Viral transduction of CD34+ cells is a promising approach for treating inherited disorders such as sickle cell disease, ß-thalassemia, or primary immunodeficiencies. An automated and functionally closed system can provide the necessary environment for GMP-compliant manufacturing of such cell therapy products.
This webinar explores Miltenyi Biotec’s automated Hematopoietic Stem Cell (HSC) Engineering process, facilitated by the CliniMACS Prodigy® Cell Manufacturing Platform.
The CliniMACS Prodigy HSC Engineering process automates the manufacturing of gene-engineered HSCs by viral transduction of human CD34+ cells. All steps are automated with manufacturing taking place in sterile, single-use tubing sets, ensuring highly reproducible and standardized manufacturing processes.
- How to enrich CD34+ cells with up to 95% purity with the CliniMACS Prodigy
- How the HSC Engineering process works and standardizes your cell manufacturing
- Which assays to perform for in-process and quality control
Lucie Stamm
Global Product Manager for the hematopoietic stem cell portfolio, Miltenyi Biotec
Lucie Stamm received her doctoral degree in Biology from the University of Cologne, Germany, in 2018. After her studies, she joined Miltenyi Biotec and currently is the Global Product Manager for the hematopoietic stem cell portfolio. Closely working together with R&D, Lucie focuses on advancing tools for the manufacturing of gene-engineered HSCs.
Katharina Krämer
Global Product Manager in the field of personalized healthcare, Miltenyi Biotec
Katharina Krämer received her master’s degree in Medical Biology from Radboud University Nijmegen, Netherlands, in 2011. After her studies, she gained extensive experience as a Global Product Manager in the field of personalized healthcare. Katharina joined Miltenyi Biotec in 2016, taking care of the CliniMACS CD34 Product Line.
Eleni Papanikolaou
Manager of Hemopoietic Stem Cell Gene Therapy and Graft Engineering, R&D, Miltenyi Biotec
Eleni Papanikolaou received her PhD from the Aristotle University of Thessaloniki in Greece and later proceeded with her postdoctoral research at the Department of Medical Genetics of the University of Washington, Seattle, enrolled in the Program of Excellence in Gene Therapy (PEGT) under the supervision of Professor George Stamatoyannopoulos, founder of the American Society of Gene and Cell Therapy (ASGCT). In 2013 she was appointed as Lecturer of Gene Therapy at the Medical School of National & Kapodistrian University of Athens, Greece and in May 2018 joined R&D at Miltenyi Biotec as a Manager of Hemopoietic Stem Cell Gene Therapy and Graft Engineering.
